Wide Ranks

ACAD

ACADIA Pharmaceuticals Inc.

16.29

Top Statistics
Market Cap 2 B Forward PE 20.66 Revenue Growth 18.30 %
Current Ratio 2.29 Trailing PE 20.88 Earnings Growth 0.00 %
Profit Margins 13.83 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 17.62 Enterprise / Revenue 2.36 Price To Sales Trailing12 Months 2.92
Profitability
Profit Margins 13.83 % Operating Margins 12.64 %
Balance Sheet
Total Cash 565 M Total Cash Per Share 3.40 Total Debt 49 M
Total Debt To Equity 8.55 Current Ratio 2.29 Book Value Per Share 3.47
All Measures
Short Ratio 748.00 % Message Board Id finmb_683713 Fax 858 212 0513
Shares Short Prior Month 8 M Return On Equity 0.2736 City San Diego
Uuid e64b7e43-7c59-3150-9bbf-f928af706124 Previous Close 16.21 First Trade Date Epoch Utc 1 B
Book Value 3.47 Beta 0.3790 Total Debt 49 M
Volume 937539 Price To Book 4.69 Fifty Two Week Low 14.15
Total Cash Per Share 3.40 Total Revenue 929 M Shares Short Previous Month Date 1 B
Target Median Price 26.00 Max Age 86400 Recommendation Mean 2.05
Sand P52 Week Change 0.3133 Operating Margins 12.64 % Target Mean Price 25.11
Net Income To Common 128 M Short Percent Of Float 0.0831 Implied Shares Outstanding 166 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 565 M Next Fiscal Year End 1 B
Revenue Per Share 5.62 Held Percent Insiders 0.0055 Ebitda Margins 13.40 %
Trailing PE 20.88 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 16.21 Target Low Price 11.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 15.62 Open 16.40 Free Cashflow 221 M
State CA Dividend Yield 0.00 % Return On Assets 0.0872
Time Zone Short Name EST Trailing Eps 0.7800 Day Low 16.15
Address1 12830 El Camino Real Shares Outstanding 166 M Price Hint 2
Target High Price 39.00 Website https://www.acadia.com 52 Week Change -0.2689
Average Volume 1 M Forward Eps 0.8200 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 196.50 % Is_sp_500 False
Regular Market Day High 16.48 Profit Margins 13.83 % Debt To Equity 8.55
Fifty Two Week High 32.59 Day High 16.48 Shares Short 10 M
Regular Market Open 16.40 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 2.36 Revenue Growth 18.30 % Shares Percent Shares Out 0.0616
Operating Cashflow 202 M Currency USD Time Zone Full Name America/New_York
Market Cap 2 B Is_nasdaq_100 False Zip 92130
Quote Type EQUITY Industry Biotechnology Long Name ACADIA Pharmaceuticals Inc.
Regular Market Day Low 16.15 Held Percent Institutions 0.9709 Current Price 16.29
Address2 Suite 400 Enterprise To Ebitda 17.62 Financial Currency USD
Current Ratio 2.29 Gross Margins 62.64 % Industry Disp Biotechnology
Number Of Analyst Opinions 19 Country United States Float Shares 108 M
Two Hundred Day Average 17.10 Ir Website http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome Enterprise Value 2 B
Price To Sales Trailing12 Months 2.92 Forward PE 20.66 Regular Market Volume 937539
Ebitda 124 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.

The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.

It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS.

The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.

ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.